209 related articles for article (PubMed ID: 22245871)
1. Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors.
Sánchez-Fructuoso AI; Ruiz JC; Calvo N; Rodrigo E; Perez-Flores I; Gómez-Alamillo C; Fernández-Pérez C; Arias M; Barrientos A
Transplantation; 2012 Feb; 93(4):398-405. PubMed ID: 22245871
[TBL] [Abstract][Full Text] [Related]
2. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
4. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
Cardinal H; Froidure A; Dandavino R; Daloze P; Hébert MJ; Colette S; Boucher A
Transplant Proc; 2009 Oct; 41(8):3308-10. PubMed ID: 19857737
[TBL] [Abstract][Full Text] [Related]
5. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
6. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies.
Chiurchiu C; Carreño CA; Schiavelli R; Petrone H; Balaguer C; Trimarchi H; Pujol GS; Novoa P; Acosta F; González C; Arriola M; Massari PU;
Transplant Proc; 2010; 42(1):277-9. PubMed ID: 20172329
[TBL] [Abstract][Full Text] [Related]
7. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
Carvalho C; Coentrão L; Bustorff M; Patrício E; Sampaio S; Santos J; Oliveira G; Pestana M
Clin Transplant; 2011; 25(4):E401-5. PubMed ID: 21457330
[TBL] [Abstract][Full Text] [Related]
8. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
[TBL] [Abstract][Full Text] [Related]
9. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients.
Martinez-Mier G; Avila-Pardo SF; Mendez-Lopez MT; Budar-Fernandez LF
Clin Transplant; 2010; 24(4):467-73. PubMed ID: 19744089
[TBL] [Abstract][Full Text] [Related]
10. Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients.
Wadei HM; Zaky ZS; Keaveny AP; Rosser B; Jones M; Mai ML; Bulatao I; Gonwa TA
Transplantation; 2012 May; 93(10):1006-12. PubMed ID: 22357174
[TBL] [Abstract][Full Text] [Related]
11. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
[TBL] [Abstract][Full Text] [Related]
12. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
13. Conversion to everolimus in kidney transplant recipients with decreased renal function.
Inza A; Balda S; Alvarez E; Zárraga S; Gaínza FJ; Lampreabe I
Transplant Proc; 2009; 41(6):2134-6. PubMed ID: 19715854
[TBL] [Abstract][Full Text] [Related]
14. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
15. Conversion to sirolimus in renal transplant recipients: a single-center experience.
Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
[TBL] [Abstract][Full Text] [Related]
16. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
Diekmann F; Budde K; Slowinski T; Oppenheimer F; Fritsche L; Neumayer HH; Campistol JM
Transpl Int; 2008 Feb; 21(2):152-5. PubMed ID: 18005087
[TBL] [Abstract][Full Text] [Related]
17. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
19. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
20. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
